REMEDENT USA INC/AZ
10QSB/A, EX-27, 2001-01-17
DRUGS, PROPRIETARIES & DRUGGISTS' SUNDRIES
Previous: REMEDENT USA INC/AZ, 10QSB/A, 2001-01-17
Next: REMEDENT USA INC/AZ, 10QSB/A, 2001-01-17


WARNING: THE EDGAR SYSTEM ENCOUNTERED ERROR(S) WHILE PROCESSING THIS SCHEDULE.

<TABLE> <S> <C>


<ARTICLE>                     5
<LEGEND>
THIS SCHEDULE  CONTAINS SUMMARY FINANCIAL  INFORMATION  EXTRACTED FROM FINANCIAL
STATEMENTS FOR THE QUARTER  ENDING JUNE 30, 2000,  JUNE 30, 1999 AND FISCAL YEAR
END MARCH  31,  2000 AND IS  QUALIFIED  IN ITS  ENTIRETY  BY  REFERENCE  TO SUCH
FINANCIAL STATEMENTS
</LEGEND>
<CIK>                         0001078037
<NAME>                        Remedent USA, Inc.
<MULTIPLIER>                                  1
<CURRENCY>                                    $

                                              June 30,
                                               2000
                                              -------
<S>                                           <C>
<PERIOD-TYPE>                                 3-MOS
<FISCAL-YEAR-END>                             MAR-31-2000
<PERIOD-START>                                APR-1-2000
<PERIOD-END>                                  JUN-30-2000
<EXCHANGE-RATE>                               1
<CASH>                                          14,869
<SECURITIES>                                         0
<RECEIVABLES>                                   57,422
<ALLOWANCES>                                    (3,000)
<INVENTORY>                                    109,643
<CURRENT-ASSETS>                               214,442
<PP&E>                                          58,810
<DEPRECIATION>                                  29,774
<TOTAL-ASSETS>                                 278,965
<CURRENT-LIABILITIES>                          847,071
<BONDS>                                              0
                                0
                                          0
<COMMON>                                        12,985
<OTHER-SE>                                    (568,108)
<TOTAL-LIABILITY-AND-EQUITY>                   278,965
<SALES>                                        200,053
<TOTAL-REVENUES>                               200,053
<CGS>                                           69,865
<TOTAL-COSTS>                                  362,281
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              62,218
<INCOME-PRETAX>                               (224,378)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                           (224,378)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (224,378)
<EPS-BASIC>
<EPS-DILUTED>





</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission